Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.53 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30054295 | 1.00 | NPSR1 (0.64) | NPSR1MAPTALDH1A1PTK2RAB9A | |
| SCHEMBL4687835 | 0.99 | NPSR1 (0.65) | NPSR1MAPTALDH1A1PTK2RAB9A | |
| SCHEMBL29538166 | 0.99 | NPSR1 (0.65) | NPSR1MAPTALDH1A1PTK2RAB9A | |
| Hydrochloric Acid SCHEMBL30722380 | 0.85 | PTK2 (0.63) | MAPTALDH1A1PTK2RAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL26987783 | 0.85 | PTK2 (0.63) | MAPTALDH1A1PTK2RAB9AL3MBTL1 | |
| SCHEMBL18869281 | 0.84 | NPSR1 (0.62) | NPSR1MAPTALDH1A1PTK2RAB9A | |
| SCHEMBL10046419 | 0.84 | RAB9A (0.70) | MAPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30481206 | 0.83 | PTK2 (0.65) | MAPTALDH1A1PTK2RAB9AL3MBTL1 | |
| SCHEMBL1503835 | 0.83 | PTK2 (0.65) | MAPTALDH1A1PTK2RAB9AL3MBTL1 | |
| SCHEMBL11732416 | 0.82 | MAPT (0.63) | MAPTALDH1A1RAB9AL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631932-A1 | PREPARATION METHOD FOR EDOXABAN AND INTERMEDIATE THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024120275-A1 | PREPARATION METHOD FOR EDOXABAN AND INTERMEDIATE THEREOF | 浙江华海药业股份有限公司 | 2024-06-13 | — | — | WO | disclosed |
| CN-118146145-A | Preparation method of ideoxaban and intermediate thereof | 浙江华海药业股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-3752488-B1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | MOEHS IBERICA SL (ES) | 2023-03-08 | — | — | EP | disclosed |
| EP-3752488-A1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | Moehs Ibérica, S.L. (ES) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019158550-A1 | METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE | MOEHS IBERICA, S.L. (ES) | 2019-08-22 | — | — | WO | disclosed |
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | APOTEX INC. (CA) | 2019-05-28 | — | — | US | disclosed |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2018-06-28 | — | — | US | disclosed |
| US-9809546-B2 | Process for producing diamine derivative | Chungwha Chemical Synthesis & Biotech Co., Ltd. (TW) | 2017-11-07 | — | — | US | disclosed |
| US-20170260138-A1 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2017-09-14 | — | — | US | disclosed |
| EP-2589590-B1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT | DAIICHI SANKYO CO LTD (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-9447118-B2 | Preparation method of optically active diamine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-20 | — | — | US | disclosed |
| EP-2980067-A1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20160016974-A1 | PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2407457-B1 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-8901345-B2 | Process for preparation of optically active diamine derivative salt | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130165657-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| EP-2589590-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-8357808-B2 | Process for producing diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20120041206-A1 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041206-A1 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE | TFPI, TFPI2, DAO | GLA 1785/4885ADRA2A 4453/4885ADRA2B 4577/4885 |
| US-20130165657-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT | TFPI, F12, TFPI2 | GLA 835/4885ADRA2A 4456/4885ADRA2B 4416/4885 |
| US-20160016974-A1 | PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND | F12, F8, F11 | GLA 258/4885ADRA2A 2124/4885ADRA2B 3544/4885 |
| US-20170260138-A1 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE | DDT, ODC1, DDC | GLA 2795/4885ADRA2A 1948/4885ADRA2B 1786/4885 |
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | VKORC1, CYP2C9, VKORC1L1 | GLA 1134/4885ADRA2A 520/4885ADRA2B 777/4885 |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | VKORC1, CYP2C9, VKORC1L1 | GLA 1134/4885ADRA2A 520/4885ADRA2B 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.